Drug profile

The FDA adverse-event record for Intranasal Bordetella Vaccine

19 FDA reports name Intranasal Bordetella Vaccine, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#1848 of 2,679
by report volume (all drugs)
19
adverse-event reports
31.6%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Intranasal Bordetella Vaccine ranks #1827 of 2679 by total reports (19). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1827
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Intranasal Bordetella Vaccine has 19 reports now versus 18 in that prior snapshot: 1 more (5.6%).

Report change
+1
Death-coded reports
+0
Death-coded share
−1.8 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Intranasal Bordetella Vaccine changes

Signature read: Intranasal Bordetella Vaccine's 31.6% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
19
Total Reports
6
Deaths Reported
31.6%
Death-coded share of reports

Active Ingredients

Intranasal Bordetella Vaccine

Administration Routes

NasalUnknown

Species Affected

Dog 19

Most Affected Breeds

Terrier - Bull - American Pit 2
Retriever - Labrador 2
Dog (unknown) 2
Terrier - Bull - Staffordshire 2
Shepherd Dog - German 2
Shih Tzu 1
Rottweiler 1
Great Pyrenees 1
Spitz - German Pomeranian 1
Dachshund (unspecified) 1

Most Reported Reactions

Vomiting 4
Death 3
Lethargy (see also Central nervous system depression in Neurological) 3
Seizure NOS 2
Falling 2
Recumbency 2
Diarrhoea 2
Blood dyscrasia NOS 2
Death by euthanasia 2
Bloody foam in mouth and nose 2
Low platelet count 2
Facial swelling (see also 'Skin') 2

Outcome Breakdown

Ongoing
8 (42.1%)
Recovered/Normal
4 (21.1%)
Died
4 (21.1%)
Euthanized
2 (10.5%)
Outcome Unknown
1 (5.3%)

Intranasal Bordetella Vaccine: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Intranasal Bordetella Vaccine (#1848 of 2,679 by report volume); death-coded 31.6%. PlainBreed drug row · death-coded share stamp 31.6% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →